[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Schrödinger, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":90},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,67],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":51,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100481055",false,"NCT05544019","Study of SGR-1505 in Mature B-Cell Neoplasms","A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies","Inclusion Criteria:\n\n* Subject must have a history of histologically or cytologically confirmed mature B-cell malignancy.\n* Subject must have measurable or detectable disease according to the applicable disease-specific classification system and meet criteria for initiation of treatment.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Life expectancy ≥ 12 weeks.\n\nExclusion Criteria:\n\n* The subject is in need of immediate cytoreductive therapy (unless the patient has no remaining treatment choice with potential benefit).\n* Subject has previous invasive malignancy in the last 2 years.\n* Subject has a known allergy to SGR-1505 or excipients of SGR-1505.\n* Subject has symptomatic or active CNS involvement of disease.\n* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that would place the participant at increased risk to the use of an investigational drug.","ALL","18 Years",{"count":18,"type":19},98,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and\u002For recommended dose (RD) of SGR-1505.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50],"Mature B-Cell Neoplasm","Non Hodgkin Lymphoma","DLBCL","Waldenstrom Macroglobulinemia","MALT Lymphoma","Follicular Lymphoma","Pediatric-Type Follicular Lymphoma","IRF4 Gene Rearrangement","EBV-Positive DLBCL, Nos","Burkitt Lymphoma","Plasmablastic Lymphoma","High-grade B-cell Lymphoma","Primary Cutaneous Follicle Center Lymphoma","Primary Effusion Lymphoma","Mantle Cell Lymphoma","DLBCL Germinal Center B-Cell Type","Primary Mediastinal Large B Cell Lymphoma","T-Cell\u002FHistiocyte Rich Lymphoma","ALK-Positive Large B-Cell Lymphoma","Primary Cutaneous Diffuse Large B-Cell Lymphoma","Splenic Marginal Zone Lymphoma","Chronic Lymphocytic Leukemia","Nodal Marginal Zone Lymphoma","HHV8-Positive DLBCL, Nos","Lymphoplasmacytic Lymphoma","Duodenal-Type Follicular Lymphoma",[52,53,28],"MALT1","NF-kB","RECRUITING","2026-02-11",{"date":57,"type":58},"2026-02-13","ACTUAL",{"date":60,"type":58},"2023-04-10",{"date":62,"type":19},"2027-11",{"name":64,"class":65},"Schrödinger, Inc.","INDUSTRY",36,{"id":68,"slug":4,"hasResults":10,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":20,"phases":75,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},"100551688","NCT06463340","Study of SGR-3515 In Participants With Advanced Solid Tumors.","A First-In-Human, Phase 1, Dose Escalation Study of SGR-3515 In Participants With Advanced Solid Tumors.","Inclusion Criteria:\n\n* Diagnosis of advanced\u002Fmetastatic solid tumor\n* Measurable disease per RECIST version 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Participant must understand and sign an Informed Consent Form (ICF) prior to any study-related assessments\u002Fprocedures\n* Adequate bone marrow and organ function\n* Women of child-bearing potential (WOCBP) or males must agree to use highly effective contraception for the duration of study and for 90 days after the last dose of study drug\n\nExclusion Criteria\n\n* Participants with primary Central Nervous System (CNS tumors).\n* Participant has received prior systemic anti-cancer treatments or other investigational agents ≤ 21 days of first dose of study drug, or 5 half-lives, whichever is shorter\n* Participant who has received definitive local control radiation (any dose greater than 50 Gy) \\\u003C 42 days prior to the first dose of study drug.\n* Participant who has received major surgeries ≤ 21 days prior to first dose of study drug\n* Participants who have not recovered to Grade 1 or baseline levels from toxicity or adverse events related to prior treatment for their cancer, excluding Grade 2 alopecia, peripheral neuropathy and ototoxicity.\n* Participant who has another clinically significant invasive malignancy, as determined by the investigator, ≤ 2 years prior to the first dose",{"count":74,"type":19},52,[22],"The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.",[78],"Advanced Solid Tumor",[80,78],"Solid Tumor","2025-07-29",{"date":83,"type":58},"2025-08-01",{"date":85,"type":58},"2024-06-18",{"date":87,"type":19},"2026-12-31",{"name":64,"class":65},14,""]